Advertisement

Drugs

pp 1–10 | Cite as

Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea

Adis Drug Evaluation
  • 55 Downloads

Abstract

Telotristat ethyl (Xermelo®), a first-in-class peripheral tryptophan hydroxylase (TPH) inhibitor, is approved to treat carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy alone. Some neuroendocrine tumours secrete serotonin (5-HT) into the blood, resulting in frequent bowel movements (BMs) and other symptoms. Telotristat ethyl inhibits TPH, thereby reducing the production of 5-HT and improving carcinoid syndrome diarrhoea. In the 12-week placebo-controlled phase of randomized trials in patients with carcinoid syndrome diarrhoea (most of whom were receiving SSA therapy), the addition of oral telotristat ethyl 250 three times daily provided significant reductions in the frequency of BMs and levels of urinary 5-hydroxyindolacetic acid (u5-HIAA; a metabolite of 5-HT) relative to placebo. Telotristat ethyl 250 mg three times daily was well tolerated, with the proportion of patients reporting at least one treatment-emergent adverse event being similar to that with placebo. With regard to adverse events of special interest, relative to placebo, telotristat ethyl had a comparable incidence of depression-related symptoms, a somewhat higher incidence of gastrointestinal (GI) disorders and a higher incidence of elevated hepatic enzyme levels.

Notes

Acknowledgements

During the peer review process, the manufacturer of telotristat ethyl was also offered the opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Katherine A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Chan DL, Singh S. Developments in the treatment of carcinoid syndrome: impact of telotristat. Ther Clin Risk Manage. 2018;14:323–9.CrossRefGoogle Scholar
  2. 2.
    Cives M, Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. Curr Treat Options Oncol. 2017;18(3):1–14.CrossRefGoogle Scholar
  3. 3.
    Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemilogy, metastatic presentation, and outcome. Cancer. 2015;121(4):589–97.CrossRefGoogle Scholar
  4. 4.
    Riechelmann RP, Pereira AA, Rego JFM, et al. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9(2):127–37.CrossRefGoogle Scholar
  5. 5.
    Alexandraki KI, Karapanagioti A, Karoumpalis I, et al. Advances and current concepts in the medical management of gastroenteropancreatic neuroendocrine neoplasms. Biomed Res Int. 2017.  https://doi.org/10.1155/2017/9856140.PubMedCentralGoogle Scholar
  6. 6.
    Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–68.CrossRefGoogle Scholar
  7. 7.
    Liu Q, Yang Q, Sun W, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther. 2008;325(1):47–55.CrossRefGoogle Scholar
  8. 8.
    Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol Sci. 2018;39(6):560–72.CrossRefGoogle Scholar
  9. 9.
    Beaumont J, Cella D, Phan A, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41:461–6.CrossRefGoogle Scholar
  10. 10.
    Goldstein G, Evans K, Shah A, et al. Carcinoid Syndrome Impact Survey: evaluation of the burden of illness and the gap between patient and oncologist perceptions [abstract no. 151 plus poster]. J Clin Oncol. 2017;35(8 Suppl):151.CrossRefGoogle Scholar
  11. 11.
    Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707–14.CrossRefGoogle Scholar
  12. 12.
    Xermelo: summary of product characteristics. London: European Medicines Agency. 2018.Google Scholar
  13. 13.
    Xermelo (telotristat ethyl) tablets, for oral use: US prescribing information. The Woodlands: Lexicon Pharmaceuticals, Inc. 2017.Google Scholar
  14. 14.
    Oravecz T, Jhaver K, Yang QM, et al. LX1606, a peripheral inhibitor of serotonin synthesis, alleviates development of inflammatory bowel disease in a preclinical model [abstract no. A128]. Inflamm Res. 2012;61(Suppl 1):S21.Google Scholar
  15. 15.
    Kim JJ, Wang H, Terc JD, et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015;309(6):G455–65.CrossRefGoogle Scholar
  16. 16.
    Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014;63(6):928–37.CrossRefGoogle Scholar
  17. 17.
    Pappas SC, Brown P, Turnage A, et al. LX1032: a potential new therapy for chronic diarrhea in carcinoid syndrome (CS) [abstract no. 352]. Gastroenterology. 2009;136(5 Suppl 1):56.Google Scholar
  18. 18.
    Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–14.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Pavel M, Hörsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–9.CrossRefGoogle Scholar
  20. 20.
    Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.CrossRefGoogle Scholar
  21. 21.
    Pavel M, Gross D, Benavant M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–22.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Hörsch D, Kulke MH, Caplin M, et al. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: analysis of the completed TELESTAR extension period [abstract]. Pancreas. 2018;47(3):341–2.Google Scholar
  23. 23.
    US National Institutes of Health. Study to compare a dose of telotristat etiprate in subjects with renal impairment with matched subjects with normal renal function [NCT03442725]. https://www.clinicaltrials.gov/ct2/show/NCT03442725?term=NCT03442725&rank=1. Accessed 6 Jun 2018.
  24. 24.
    US National Institutes of Health. Study to evaluate the pharmacokinetics of telotristat ethyl in subjects with severe hepatic impairment [NCT03423446]. https://www.clinicaltrials.gov/ct2/show/NCT03423446?term=NCT03423446&rank=1. Accessed 6 Jun 2018.
  25. 25.
    Weickert MO, Kaltsas G, Hörsch D, et al. Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clin Ther. 2018.  https://doi.org/10.1016/j.clinthera.2018.04.006 (Epub 2018. pii: S0149-2918(18)30148-6).Google Scholar
  26. 26.
    Cella D, Beaumont J, Hudgens S, et al. Relationship between symptoms and HRQoL benefits in patients with carcinoid syndrome (CS): a post-hoc analysis of telotristat ethyl (TE) TELESTAR trial [abstract no. M3 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):232.Google Scholar
  27. 27.
    Anthony LB, Kulke MH, Hörsch D, et al. Impact of concomitant medication on efficacy of telotristat ethyl: a post hoc subgroup analysis of the phase 3 TELESTAR study in carcinoid syndrome [abstract no. L2 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):212.Google Scholar
  28. 28.
    Dillon JS, Kulke M, Pavel M, et al. Time to sustained improvement in bowel movement frequency with telotristat ethyl: analysis of the phase 3 TELESTAR study [abstract]. Pancreas. 2018;47(3):337–8.Google Scholar
  29. 29.
    Pavel M, Hörsch D, Hoffmanns P, et al. Correlation of plasma (p) and urine (u) 5-HIAA levels in patients (pts) with carcinoid syndrome: post-hoc analyses from the TELESTAR study [abstract no. M8 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):237.Google Scholar
  30. 30.
    Kulke M, Hörsch D, Caplin M, et al. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome [abstract no. 422PD]. Ann Oncol. 2016;27(Suppl 6):vi136–48.Google Scholar
  31. 31.
    Lapuerta P, Kulke MH, Caplin M, et al. Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl [abstract no. 442P plus poster]. Ann Oncol. 2017;28(Suppl 5):147–8.Google Scholar
  32. 32.
    Lapuerta P, Kulke M, Pavel M et al. Integrated safety analysis of telotristat ethyl in patients with carcinoid heart disease [abstract no. L7 plus poster]. In: 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease [abstract booklet]. Berlin: European Neuroendocrine Tumor Society. 2017. p. 237.Google Scholar
  33. 33.
    Kasi PM. Telotristat ethyl for patients with carcinoid syndrome associated with chest pain and hypertension [letter]. Pancreas. 2018;47(1):e2.  https://doi.org/10.1097/MPA.0000000000000971.CrossRefGoogle Scholar
  34. 34.
    National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Neuroendocrine and adrenal tumors (version 2.2018). Fort Washington: National Comprehensive Cancer Network®, Inc. 2018.Google Scholar
  35. 35.
    Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ. 2017;21(2):182–8.CrossRefGoogle Scholar
  36. 36.
    Joish VN, Frech F, Lapuerta P. Budgetary impact of telotristat ethyl, a novel treatment for carcinoid syndrome diarrhea patients: a US health plan perspective. Clin Ther. 2017;39(12):2338–44.CrossRefGoogle Scholar
  37. 37.
    Fust K, Maschio M, Pastor L, et al. A budget impact model of the addition of telotristat ethyl treatment in patients with uncontrolled carcinoid syndrome [abstract no. PSY25 plus poster]. Value Health. 2017;20(9):A548–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations